证券代码：002817 证券简称：黄山胶囊 公告编号：2025-020 安徽黄山胶囊股份有限公司 经审核，监事会认为：公司 2025 年半年度报告及其摘要的编制和审议程序 符合法律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反映了 公司的财务状况和经营成果，不存在任何虚假记载、误导性陈述或者重大遗漏。 《公司 2025 年半年度报告》《2025 年半年度报告摘要》详见公司指定信息 披 露 媒 体 《 证 券 时 报 》《 上 海 证 券 报 》《 中 国 证 券 报 》 和 巨 潮 资 讯 网 （http://www.cninfo.com.cn）。 表决结果：同意 3 票，反对 0 票，弃权 0 票。 三、备查文件 1. 第五届监事会第十三次会议决议。 安徽黄山胶囊股份有限公司（以下简称"公司"）第五届监事会第十三次会 议（以下简称"本次会议"）通知于 2025 年 8 月 15 日以电话、电子邮件等方式 发出，并于 2025 年 8 月 22 日在公司一楼会议室以现场结合通讯的方式召开。本 次会议由监事会主席张新华先生主持，部分高级管理人员列席了会议，本次会议 应到监事 3 名，实到监事 3 名 ...

证券代码：002817 证券简称：黄山胶囊 公告编号：2025-019 安徽黄山胶囊股份有限公司 第五届董事会第十三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 安徽黄山胶囊股份有限公司（以下简称"公司"）第五届董事会第十三次会 议（以下简称"本次会议"）的通知已于 2025 年 8 月 15 日以电话、电子邮件等 方式向全体董事发出。本次会议于 2025 年 8 月 22 日在公司一楼会议室以现场结 合通讯方式召开，应到董事 7 名，实到董事 7 名，其中王清华女士以通讯表决方 式出席。本次会议由董事长李合军先生主持，公司监事和高级管理人员列席了会 议。本次会议的通知、召集、召开、审议、表决程序均符合有关法律、行政法规、 规范性文件和《公司章程》的规定，会议形成的决议合法、有效。 二、董事会会议审议情况 1. 第五届董事会第十三次会议决议； 1. 审议通过《公司 2025 年半年度报告及其摘要》 《公司 2025 年半年度报告》《2025 年半年度报告摘要》详见公司指定信息 披 露 媒 体 《 证 券 时 报 》《 ...

Financial Performance - The company's operating revenue for the first half of 2025 was ¥243,881,502.87, representing a 3.66% increase compared to ¥235,268,376.00 in the same period last year[22]. - The net profit attributable to shareholders was ¥35,552,521.32, a 19.78% increase from ¥29,682,423.79 year-on-year[22]. - The net profit after deducting non-recurring gains and losses was ¥34,398,836.32, up 23.53% from ¥27,847,641.38 in the previous year[22]. - The basic earnings per share rose to ¥0.12, a 20.00% increase from ¥0.10 in the previous year[22]. - The company achieved operating revenue of 243.88 million yuan, an increase of 3.66% compared to the previous year[36]. - Net profit attributable to shareholders reached 35.55 million yuan, reflecting a growth of 19.78% year-over-year[36]. - The company's revenue for the reporting period was ¥243,881,502.87, representing a year-on-year increase of 3.66% compared to ¥235,268,376.00 from the previous year[45]. - The company achieved a net cash flow from operating activities of ¥29,102,797.29, a significant increase of 355.30% from a negative cash flow of ¥11,399,312.29 in the previous year[45]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,109,638,569.04, reflecting a 2.13% increase from ¥1,086,534,605.98 at the end of the previous year[22]. - The net assets attributable to shareholders increased by 2.64% to ¥940,599,777.94 from ¥916,439,508.41 at the end of the previous year[22]. - The company’s cash and cash equivalents decreased to ¥291,927,945.73, accounting for 26.31% of total assets, down from 31.44% the previous year[49]. - Total current assets decreased from ¥590,012,632.85 to ¥568,315,561.21, indicating a decline of about 3.7%[107]. - Total liabilities decreased to ¥167,484,316.97 from ¥168,773,049.88, reflecting a decline of about 0.8%[109]. - Owner's equity increased to ¥942,154,252.07 from ¥917,761,556.10, marking an increase of approximately 2.6%[109]. Market and Competition - The company is facing increased competition in the hollow capsule market due to anti-dumping and countervailing duties imposed by the U.S., with a comprehensive tax rate of 136.14% applicable to its exports[30]. - The revenue proportion of enteric-coated gelatin capsules and plant-based capsules increased from 26.17% to 35.46% compared to the same period last year[36]. - The company focuses on high-end market development and has improved its product structure significantly[36]. - The company plans to enhance its production capabilities in high-end pharmaceutical excipients, aligning with national industrial guidance[30]. Research and Development - The R&D investment for the reporting period was ¥6,063,998.06, which is a decrease of 9.10% compared to ¥6,670,795.43 in the previous year[45]. - The company has developed core technologies in enteric coating materials and has received multiple invention and design patents[40]. - The company plans to invest 100 million yuan in research and development for new technologies in the upcoming year[129]. - Research and development expenses have increased by 15% compared to the previous year, reflecting the company's commitment to innovation[135]. Cash Flow and Financing - Operating cash flow for the first half of 2025 was ¥29,102,797.29, a significant improvement compared to a negative cash flow of ¥11,399,312.29 in the first half of 2024, indicating a turnaround in operational efficiency[121]. - The company reported a net cash outflow from financing activities of ¥19,765,380.37 in the first half of 2025, compared to a larger outflow of ¥26,687,739.70 in the first half of 2024, showing a reduction of about 26%[122]. - The total cash inflow from investment activities in the first half of 2025 was ¥54,901,664.40, significantly higher than ¥11,108,076.00 in the first half of 2024, marking an increase of approximately 393%[122]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 17,906[96]. - Shandong Lutai Holding Group Co., Ltd. holds 29.99% of shares, totaling 89,699,541 shares[96]. - The total number of shares before the recent change was 299,098,170, with the same number after the change[95]. - The proportion of limited sale condition shares remained at 3.03% after the change[94]. Future Outlook - Future outlook indicates a focus on expanding market presence, targeting a 10% increase in market share by the end of 2025[128]. - The company is considering potential acquisitions to enhance its product portfolio, with a budget of 200 million yuan allocated for this purpose[128]. - The overall capital expenditure for the year is projected to be 300 million yuan, focusing on production capacity enhancement[129]. - The company aims to improve operational efficiency by 5% through strategic cost management initiatives[130]. Compliance and Governance - The financial statements have been prepared in accordance with the relevant accounting standards, ensuring transparency and compliance with regulatory requirements[145]. - The company has not identified any significant doubts regarding its ability to continue as a going concern for the next 12 months, ensuring stability for stakeholders[143]. - There were no significant legal disputes or penalties during the reporting period[75][76].

Company Overview - Huangshan Capsule Co., Ltd. specializes in the research, production, and sales of gelatin hollow capsules and enteric-coated gelatin hollow capsules, being one of the earliest manufacturers in China with over thirty years of high-quality production history [1][2] - The company has a strong reputation in the pharmaceutical hollow capsule industry and is a member of the China Pharmaceutical Packaging Association, recognized for its contributions [1] Financial Performance - For Q1 2025, the company reported revenue of 119 million yuan, a year-on-year increase of 0.53%, and a net profit of 18.837 million yuan, reflecting a year-on-year growth of 22.90% [2] - The sales gross margin for the same period was 29.26% [2] Market Position - As of August 19, the company's stock closed at 8.06 yuan, with a PE ratio of 45.69, compared to the industry average of 59.49 and the industry median of 40.19 [1][2] - The total market capitalization of Huangshan Capsule is 2.411 billion yuan [1] Shareholder Information - As of March 31, 2025, the number of shareholders is 18,378, a decrease of 26 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1]

Core Insights - Huangshan Capsule's stock closed at 8.18 yuan, up 1.11%, with a rolling PE ratio of 46.37 times and a total market capitalization of 2.447 billion yuan [1] - The company operates in the medical device industry, which has an average PE ratio of 55.70 times and a median of 39.08 times, placing Huangshan Capsule at the 84th position in the industry ranking [1] - As of the first quarter of 2025, only one institution holds shares in Huangshan Capsule, with a total of 18,000 shares valued at 0.00 billion yuan [1] Company Overview - Anhui Huangshan Capsule Co., Ltd. specializes in the research, production, and sales of gelatin hollow capsules and enteric-coated gelatin hollow capsules [1] - The company is one of the earliest manufacturers of medicinal hollow capsules in China, boasting over 30 years of high-quality production history [1] - Huangshan Capsule has a strong reputation in the medicinal hollow capsule industry and is a member of the China Pharmaceutical Packaging Association, recognized for its contributions [1] Financial Performance - In the first quarter of 2025, the company reported an operating income of 119 million yuan, a year-on-year increase of 0.53%, and a net profit of 18.837 million yuan, reflecting a year-on-year growth of 22.90% [2] - The sales gross margin for the company stands at 29.26% [2] Industry Comparison - Huangshan Capsule's PE (TTM) is 46.37, compared to the industry average of 55.70 and the industry median of 39.08 [2] - The company’s market capitalization is 2.447 billion yuan, while the industry average market capitalization is 11.731 billion yuan [2]

Core Insights - The report highlights the importance of CFOs in listed companies, with the total salary scale for CFOs in A-share companies reaching 4.27 billion yuan in 2024 [1] - The average annual salary for CFOs in the raw material pharmaceutical sector is 661,200 yuan [1] Salary Distribution - The top three highest-paid CFOs are Gong Yuda from Guobang Pharmaceutical with 1.93 million yuan, Li Qirong from Zhejiang Pharmaceutical with 1.84 million yuan, and Hou Ning from Xinhua Pharmaceutical with 1.57 million yuan [1] - The salary distribution shows that 44% of CFOs earn below 500,000 yuan, 44% earn between 500,000 and 1 million yuan, and 12% earn above 1 million yuan [1] Age and Education Distribution - CFOs aged 40-50 constitute the majority at 36%, while those aged 60 and above account for 5% [1] - The educational background of CFOs shows that 65% hold a bachelor's degree, 21% have a master's degree, and only 2% have a high school diploma [1] Salary Changes - Liu Qingke from Huangshan Capsule experienced the largest salary decrease at 19.04%, while Qian Dan from Nengte Technology saw the highest salary increase at 100.58% [1]

Group 1 - The total salary scale of CFOs in A-share listed companies reached 4.27 billion yuan in 2024, with an average annual salary of 814,800 yuan [1] - Among the CFOs, those aged 40-50 represent the majority at 36%, while those aged 60 and above account for 5% [1] - The youngest CFO currently in office is 33 years old, from XinNuoWei, named Dai Long [1] Group 2 - The average annual salary of CFOs in the A-share raw material pharmaceutical companies is 661,200 yuan [2] - The salary distribution shows that 44% of CFOs earn below 500,000 yuan, while another 44% earn between 500,000 and 1 million yuan, and 12% earn above 1 million yuan [2] - The top three highest-paid CFOs are Gong Yuda from Guobang Pharmaceutical at 1.93 million yuan, Li Qirong from Zhejiang Pharmaceutical at 1.84 million yuan, and Hou Ning from Xinhua Pharmaceutical at 1.57 million yuan [2]

Core Viewpoint - Huangshan Capsule's stock closed at 8.19 yuan on August 4, with a 1.74% increase, and a rolling PE ratio of 46.43, marking a new low in 373 days, with a total market value of 2.45 billion yuan [1] Company Overview - Anhui Huangshan Capsule Co., Ltd. specializes in the research, production, and sales of gelatin hollow capsules and enteric-coated gelatin hollow capsules, being one of the earliest manufacturers in China with over 30 years of high-quality production history [1] - The company has a strong reputation in the pharmaceutical hollow capsule industry and is a member of the China Pharmaceutical Packaging Association, recognized for its contributions [1] Financial Performance - In the latest quarterly report for Q1 2025, the company achieved an operating income of 119 million yuan, a year-on-year increase of 0.53%, and a net profit of 18.837 million yuan, reflecting a year-on-year growth of 22.90%, with a gross profit margin of 29.26% [2] Market Position - Huangshan Capsule's PE ratio of 46.43 is below the industry average of 54.31 and the industry median of 38.11, ranking 84th in the medical device sector [1][2] - The company’s market value stands at 2.45 billion yuan, compared to the industry average market value of 11.617 billion yuan [2] Capital Flow - On August 4, the net inflow of main funds into Huangshan Capsule was 764,500 yuan, although the overall trend over the past five days showed a net outflow of 4.3336 million yuan [1]

Core Insights - The report highlights that in 2024, the total salary for A-share listed company secretaries reached 4.086 billion yuan, with an average annual salary of 708,000 yuan [1] - A total of 1,144 company secretaries earned over 1 million yuan, accounting for more than 21% of the total [1] Salary Distribution - The average annual salary for company secretaries in the A-share raw material pharmaceutical sector is 608,400 yuan [2] - The distribution of salaries shows that 49% earn below 500,000 yuan, 40% earn between 500,000 and 1 million yuan, and 11% earn above 1 million yuan [2] - The top five highest-paid company secretaries have annual salaries of 1.9309 million yuan, 1.514 million yuan, 1.2 million yuan, 1.17 million yuan, and 1.1 million yuan respectively [2] Age and Education Distribution - Company secretaries aged between 30 and 50 constitute 60% of the market, while those over 50 account for 38%, and those aged 30 or below make up 2% [1] - More than half of the company secretaries hold a bachelor's degree, with 9% having an associate degree, 52% a bachelor's degree, and 39% a master's degree [1] Investor Engagement - There is significant variation in the number of investor meetings held by companies, with 43% of companies hosting fewer than 10 meetings annually [2] - The top five companies with the most investor meetings conducted 520, 437, 325, 323, and 291 meetings respectively [3]

董秘作为连接投资者与上市公司的"桥梁"，在上市公司资本运作中发挥着关键作用。新浪财经《2024年 度A股董秘数据报告》显示，2024年A股上市公司董秘薪酬合计达40.86亿元，平均年薪75.43万元。 年薪不足20万的董秘共三人，分别为新天地的谢雨珊、东亚药业的周剑波、欧康医药的曹永强，三人 2024年年薪分别为17.42万元、18.75万元、19.07万元。从任职年限看，三位薪酬最低董秘均为近两年任 职。 从接待投资者次数看，各上市公司接待情况差异较大。经统计，年接待次数小于10次的公司数量为20 家，占比43%；接待次数为10次-100次的公司数量为19家，占比40%；接待次数为100次-300次的公司数 量为4家，占比8%；接待次数为300次-1000次的公司数量为4家，占比8%。 其中，接待投资者次数0次的公司共5家，分别为奥翔药业、川宁生物、新赣江、峆一药业、新天地。 分行业来看，统计数据显示，A股共有47家上市原料药公司，董事会秘书聘任总体情况如下（部分统计 口径剔除无效数据）。 从董秘的年龄分布来看，介于30-50岁的董秘是市场的中坚力量，占比共计达到60%；50岁以上的董秘 占比为38%；小于 ...